secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0000950170-25-043809
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences Q4/FY2024 results: net loss $86.9M, cash $151.1M, Phase 3 CoMpass actively enrolling
--------------------------------------------------------------------------------

- Net loss $86.9M in FY2024 vs $76.4M in FY2023; R&D expenses $73.3M.
- Cash $151.1M as of Dec 31, 2024; runway into 2H 2026.
- Phase 3 CoMpass trial actively enrolling; >175 patients pre-screened globally since June 2024.
- Phase 2 trial in choroidal metastases initiated; initial data expected 2025.
- Phase 1 NMIBC data showed clinical complete responses; Tony Gibney appointed Senior Finance and Strategy Advisor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000095017025043809/0000950170-25-043809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000095017025043809/aura-20250324.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-043809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer